NASDAQ:GRCE

Grace Therapeutics Q3 2025 Earnings Results & Report

Grace Therapeutics logo
$1.71 -0.02 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 -0.01 (-0.35%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics beat analyst earnings expectations in its Q3 2025 results, released February 13, 2025. The company reported EPS of -$0.26 versus the -$0.27 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 PM ET

Grace Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Q3 2025 Earnings FAQ

Grace Therapeutics (NASDAQ:GRCE) reported earnings of -$0.26 per share for Q3 2025, beating the consensus estimate of -$0.27. The report was announced on Thursday, February 13, 2025.

Grace Therapeutics Earnings Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
Grace: Fiscal Q2 earnings snapshot
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders.

The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.

View Grace Therapeutics Profile